When a T cell encounters a tumor, immunology has focused on the informational exchange. The cancer cell presents antigens — or hides them. Checkpoint proteins signal “don't attack” — or get blocked by therapy. The battle is understood as recognition and deception: the immune system searches for molecular identity, and the tumor disguises itself.
A Nature study (Baldwin et al., 2025) reveals a second front that operates below the informational layer: the tumor sabotages the T cell's metabolism by swapping mitochondria. Through tunneling nanotubes — thin cytoplasmic bridges that connect cells — the cancer cell steals functional mitochondria from T cells and transfers its own mutant mitochondria back. The T cell receives organelles carrying mitochondrial DNA mutations that impair oxidative phosphorylation, increase reactive oxygen species, and drive the cell toward senescence. The tumor, now running on stolen healthy mitochondria, gains metabolic advantage.
The mechanism is bidirectional. It is not simply that cancer cells shed damaged parts; they actively harvest the working ones. The tunneling nanotube formation is induced by oxidative stress — the same damage that accumulates in the tumor microenvironment creates the physical channels through which the swap occurs. The damage builds its own distribution system.
The result: T cells that have infiltrated the tumor — the ones that successfully recognized the cancer and migrated to it — become metabolically impaired not because they were tricked into ignoring the target, but because their engines were replaced with defective ones. Recognition succeeded. The kill mechanism was disarmed after recognition, not before.
This explains a clinical pattern. Checkpoint inhibitors like anti-PD-1 therapy restore the informational signal — they remove the “don't attack” brake. But patients whose tumor-infiltrating lymphocytes carry tumor-derived mitochondrial DNA mutations respond poorly. The brake is released, but the engine is broken. The car doesn't move.
The structural insight: immune evasion is not one strategy. The informational channel (antigen presentation, checkpoint signaling) and the metabolic channel (mitochondrial integrity, energy supply) are independent axes of attack. A therapy that restores one leaves the other untouched. The cancer survives checkpoint blockade not by re-hiding its antigens but by having already crippled the machinery that would act on recognition. The evasion is not in being unseen. It is in disarming the thing that sees.